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Extraction methods that simulate those used in the clinic are recommended for obtaining extraction solutions. For
polyvinyl chloride (PVC) medical devices that have contact with human blood, an alternative medium (ethanol/
water mixture) is suggested as an extraction screening vehicle to evaluate the di(2-ethylhexyl)phthalate (DEHP)
released. A test comparing the extraction ability between the alternative medium and whole blood from three
healthy volunteers has been conducted. An experimental method is provided outlining the chemical analysis of the
DEHP released from medical devices made with polyvinyl chloride (PVC). Gas chromatography-mass spectrometry
(GC-MS) in the selective ion monitoring (SIM) mode was used to analyze and quantify the extracted DEHP. The
linear range of the SIM method was 0.1-200 μg/mL, and the recoveries were 89.6-101.5% and 91.0-98.9% when
using the ethanol/water mixture and whole blood as the extraction media, respectively. The validated method
demonstrates that it is suitable for the determination of the DEHP released from PVC medical devices that have
contact with blood. The results from the determination of the DEHP released will be compared with the limits
derived from toxicological data for the parenteral exposure route and certain population groups, and the results
will be used in the risk assessment of medical devices.
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Gas chromatography/mass spectrometry (GC-MS); Blood contactIntroduction
Patients undergoing medical procedures, such as intravas-
cular therapy, parenteral nutritional support, blood transfu-
sions, hemodialysis, cardiopulmonary bypass (CPB) and
extracorporeal membrane oxygenation (ECMO), can be ex-
posed to di-(2-ethylhexyl)phthalate (DEHP), a compound
used as a plasticizer in polyvinyl chloride (PVC) medical
devices. DEHP has been shown to produce a wide range of
adverse effects in experimental animals, most notably liver
toxicity and testicular atrophy. Although the toxic and
carcinogenic effects of DEHP have been well established in
experimental animals, the ability of this compound to* Correspondence: luohongyu157@163.com
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in any medium, provided the original work is pproduce adverse effects in humans is controversial. As a re-
sult, the ability of DEHP and other phthalate esters to pro-
duce adverse effects in humans has been a topic of active
discussion and debate in the scientific and regulatory com-
munities (U.S.FDA 2001). Since 2001, several countries
have initiated safety assessments of DEHP-plasticized PVC
medical devices (U.S.FDA 2001; European Commission,
2008; Health Canada 2001; BfArM Germany 2004). In a U
S Food and Drug Administration (FDA) report, the toler-
able intake (TI) values for two DEHP exposure routes were
derived from the available toxicity data. The TI values for
the parenteral and oral routes are 0.60 mg/kg/day and
0.04 mg/kg/day, respectively (U.S.FDA 2001).
Over the past few decades, there have been various
DEHP-plasticized PVC medical devices used in clinics,
such as blood bags, infusion or transfusion tubings, en-
teral and parenteral nutritional tubings, cardiopulmo-
nary bypass tubings, hemodialysis systems, various tube
systems for blood cell separation machines, heat lungOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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widely used devices, nearly half come into contact with
human blood or blood components.
For the purpose of assessing the safety of the DEHP
released from medical devices during clinical use, an ex-
traction method simulating clinical use would normally
be used. In a study focusing on donor exposure to
DEHP during plateletpheresis, the blood of 36 healthy
donors undergoing plateletpheresis with either continu-
ous or discontinuous apheresis devices was collected,
and the serum concentrations of DEHP were determined
(Buchta et al. 2003). In two other studies, DEHP exposure
was assessed in 11 patients and 21 patients with chronic
renal failure undergoing maintenance hemodialysis (Dine
et al. 2000; Faouzi et al. 1999). Other studies that have
been conducted include the evaluation of the DEHP ex-
posure of voluntary plasma and platelet donors (Koch
et al. 2005a; Koch et al. 2005b). Studies on the types of
medical devices that have contact with blood usually need
to recruit volunteers or study blood collected from pa-
tients. However, with such a large variety of devices being
used during clinical therapeutic procedures, it is very diffi-
cult or impractical to conduct the study in patients or vol-
unteers when a certain type of exposure assessment is
needed and an alternative contact medium is preferred.
This is especially true when the medical device is still in
pre-market evaluation stages and cannot be used on hu-
man beings. In a risk assessment study of the DEHP re-
leased from PVC blood circuitry during hemodialysis and
pump-oxygenation therapy, fresh bovine blood containing
heparin (10,000 U/L) was used as the contact medium in-
stead of human blood (Haishima et al. 2004), and it was a
good and reasonable choice. Even so, it may still not be
very convenient to perform these studies in a laboratory.
In this study, an ethanol/water mixture with a density
from 0.9373 to 0.9378 g/ml is recommended as a blood al-
ternative, and the mixture is also available as an alternative
extraction medium in accordance with ISO3826-1 (ISO
3826-1 2003). This mixture has also been adopted by
the European Pharmacopoeia as the extraction vehicle
for the evaluation of the DEHP extracted from blood
bags (European Pharmacopoeia 7.0). However, when
reviewing the test method in both of the documents
above, it may be considered an accelerated test method.Figure 1 Chromatogram of the DEHP standard solution (10 μg/mL) inBriefly, this alternative solvent was used to fill up a
blood bag to half the amount of its nominal capacity,
and after releasing the air from the bag and incubating
it at 37 ± 1°C for 60 ± 1 min, a UV/VIS spectrophotom-
eter was utilized at 272 nm to determine the amount of
DEHP. Thus, in addition to using the alternative solu-
tion, the test method neither simulated the practical
use of the device nor the specific for analysis in most
cases. For example, the blood bag was normally manu-
factured without the use of any adhesives, but many of
the tubes would use, which might be an interfering fac-
tor when using UV/VIS spectrophotometer. In this
study, blood has been collected from 3 healthy volun-
teers to compare the DEHP extracting abilities of the
alternative solution and human whole blood.
There are various analytical methods that can be used
to quantitatively determinate the extracted DEHP, includ-
ing GC, HPLC, GC-MS, LC-MS and even a UV spectro-
photometric method (ISO 3826-1 2003; Haishima et al.
2005; Inoue et al. 2005; Han et al. 2005; Ito et al. 2005;
Chiellini et al. 2011). Due to the variety of medical devices
made with PVC on the market as well as the various
intended clinical uses, there is no universal evaluation
method for all intended purposes of medical devices made
with PVC. In this study, a GC-MS method was used for
determination of the released DEHP. The validation of the
method included evaluating the precision, accuracy, lin-
earity, sensitivity and selectivity (ICH Q2R1 2005).
The goal of the present study is to recommend and valid-
ate an alternative extraction solution for medical devices
that have contact with human blood or blood components
to use as a screening test for the evaluation of the DEHP
released from PVC products. The GC-MS method was
established and validation of the methodology was con-
ducted for both the alternative (ethanol/water mixture) and
whole blood extractions. The results of the DEHP determi-
nations were then compared with the DEHP tolerable ex-
posure limits as part of the risk assessment of the products.
Experimental
Chemicals and reagents
The DEHP standard was purchased from AccuStandard
(125 Market St. New Haven, CT 06513, USA). Ethanol,
which was used as part of the extraction solution, wasthe SIM Mode.
Figure 2 Chromatogram of the sample solution (ethanol/water mixture) in the SIM Mode.
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mine the DEHP background and was purchased from
Merck KGaA (Darmstadt, Germany). n-Hexane of a
grade suitable for liquid chromatography was used as
the solvent of the working standard and as a dissolving
regent during the sample preparation procedure. It had
been screened for its DEHP background and was pur-
chased from Merck KGaA (Darmstadt, Germany). In
addition, the disodium salt of EDTA and heparin sodium
salt, which were used in this paper as anticoagulants when
collecting blood, were purchased from the Xilong Chem-
ical Factory (Guangdong, China) and Sigma (3050 Spruce
Street, St Louis, USA), respectively. The pure water used
as part of the extraction solution was prepared using an
ULTRAPURE purification system (Shanghai, China) at a
resistance greater than 18 Ω.Preparation of the working standards
Approximately 20 mg of the DEHP standard was accur-
ately weighed out and diluted with n-hexane to 10 mL
in a volumetric flask. This solution was labeled the
2000 μg/mL stock standard and was stored in the fridge.
The solution is stable for 1 month. According to the re-
leased DEHP level in the sample solution or its predicted
level, a proper working standard range within the linear
range of 0.1 μg/mL-200 μg/mL was selected. The stock
standard was diluted stepwise with n-hexane to prepare
at least 5 concentrations of working standards. For the
whole blood sample, a spiked standard method was used
because of its relatively complicated matrix.Figure 3 Chromatogram of the sample solution (blood) in the SIM MoSample preparation
General
In principle, the method for DEHP extraction from PVC
medical devices usually takes into account the intended
clinical use of the medical device. For example, in medical
devices contacting blood, such as a dialyzer, oxygenator, or
blood circuit, an appropriate amount of anticoagulant, such
as a heparin salt or an ethylenediamine-tetraacetic acid
(EDTA) salt, is added into the blood and circulated into
the system under the same conditions as those for clinical
use (circulation time, circulation rate and temperature),
and a suitable amount of the circulated blood is collected
as the test sample. In addition, an ethanol/water mixture
with a density from 0.9373 to 0.9378 g/mL is suggested as
an alternative solution in this paper for a screening test to
evaluate the DEHP released from devices that contact
blood.Extraction with ethanol/water
It may not be very practical or convenient to use blood
or its components as the extraction media to evaluate
the DEHP released from medical devices because in
many cases, it is difficult to collect enough blood or to
recruit enough volunteers for the study. Especially for
products in a preclinical stage, it is almost impossible to
collect body fluids from patients, and a simulated
method may be preferred. Even for a post-market prod-
uct intended to perform this determination, it may be
not convenient to recruit volunteers or collect samples
from patients. In these situations, the use of an alternativede.
Figure 4 MS Spectrum of the DEHP standard and the ethanol/water mixture sample solution. [Note (a) for standard and (b) for
sample solution].
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water mixture with a density from 0.9373 to 0.9378 g/mL
as an alternative extraction vehicle instead of blood and
following the procedures described in the General section
or other procedures has been justified. The density of the
ethanol/water mixture, which ranged from 0.9373 g/ml to
0.9378 g/ml (20°C), was determined with a pycnometer.
(ISO 3826-1 2003).
A certain amount of the extracted sample was taken
and dried at 50°C under vacuum in a vacuum drying
oven to complete dryness. The sample was equilibrated
to room temperature and an equal volume of n-hexane
was added and followed by vortexing the solution vig-
orously for 1 min. This constituted the sample solution.
If the result of the determination of DEHP was accept-
able compared with the limit of tolerable exposure for
human beings, no further tests were needed on the
blood.Figure 5 Chromatogram of the n-hexane regent screened in the SIMExtraction with blood
If the released DEHP determination result with the alter-
native media is not acceptable, an extraction with blood
may be used.
The extraction solution was prepared using the
method described in the General section above or an-
other method that has been justified with blood contain-
ing anticoagulants (EDTA salts or heparin, etc). Then,
0.5 mL of extraction solution was transferred into centri-
fuge tubes, 2 mL of n-hexane was added, and the solu-
tion was vortexed for 1 min. It was then centrifuged for
10 min at 3000 rpm, and the supernatant (n-hexane
layer) was considered the sample solution.
GC-MS conditions
GC-MS was conducted using an Agilent 7890 GC and an
Agilent 5975C mass spectrometer equipped with an elec-
tron ionization (EI) source and a quadrupole analyzer.Mode.
Table 1 Comparison of the extractions between blood
and the water/ethanol mixture
Blood group
(DEHP released, mg) Water/ethanol
mixture group (DEHP released, mg)
1a 2a 3a
0.110 0.068 0.073 2.84
aThe numbers 1, 2, and 3 correspond to whole blood samples from
three volunteers.
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0.25 mm × 0.25 μm, Agilent J & W GC columns, USA).
The fragment ion with a m/z = 149 was selected for the
GC-MS SIM detection. The ion source and inlet tempera-
tures were 230°C and 280°C, respectively. In addition, the
quadrupole and auxiliary temperatures were 150°C and
280°C, respectively. A split ratio of 5:1 was used, and a
mass scan range from 45-450 amu was employed. The EI
energy was 70 eV. The starting column temperature was
150°C, which was held for 0.5 min, and the temperature
was then raised to 280°C at 20°C/min, where it was held
for 7 min. In addition, the gas flow was set at 1.5 mL/min,
and the solvent delay time was 3.5 min. Figures 1, 2, 3 and




Phthalates began to be used in the plastics industry
more than 80 years ago. DEHP is added to PVC material
that is used in food packaging material, medical prod-
ucts, plastic toys, vinyl upholstery, shower curtains, ad-
hesives, and coatings (Fernández et al. 2012). Various
phthalate esters have been reported to be present in the
environment, including in outdoor air, water, soil, in-
door air and dust, sediment, seafood and human tissue
(Fernández et al. 2012; Zeng et al. 2011; Santhi andFigure 6 Comparison of the extractions with blood and the water/ethMustafa 2013). As a result, during the test procedure,
reducing the DEHP background that may result from
reagents, utensils and instrument systems to levels as
low as possible is necessary. In this study, all of the re-
agents, especially the n-hexane used in standard and
sample preparation, were subjected to DEHP back-
ground screening to ensure that the target chemical
was at the lowest level possible. The same screening
was applied to ethanol. In some cases, there were very
different levels of DEHP background in the screened
regents even though all of them are labeled as chroma-
tography grade.
Another important factor that can contribute to back-
ground DEHP is the utensils; in this study, all of the uten-
sils used were made of glass to avoid DEHP being released
from plastic utensils. Pretreatment of the utensils to re-
duce any DEHP residue on them was performed. Usually
utensils are heated to high temperatures, such as to 250°C
for more than 10 h or to 400°C for 2 h (Haishima et al.
2005; Loff et al. 2004). However, in this study, some of the
utensils, such as transfer pipettes and volumetric flasks,
are used for accurately transferring solutions or to prepare
the standard solutions, and it is recommended suggested
that they are not heated to high temperatures after cali-
bration. Therefore, these types of glass utensils were
rinsed with n-hexane that was previously screened for
background DEHP (see Figure 5) and were individually
validated using the previously described GC-MS condi-
tions to ensure the DEHP background was as low as
possible.
Comparison between the extraction abilities of the
water/ethanol mixture and blood
A considerable number of medical devices made from
PVC material come into contact with blood or blood com-
ponents during use. Although there is much literatureanol mixture.









Very low (0.1)a 7693 299 3.88
Low (1.0) 215724 3347 1.55
Intermediate (50.1) 14429286 502984 3.48
High (200.6) 48864521 1841486 3.76
aThis concentration was tested at a different time and did not exhibit linearity
with the other concentrations.
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blood, plasma or serum, it is not very practical to use
blood or its components as extraction media to evaluate
the DEHP released from medical devices everytime the
equipment is used.
In this study, blood samples from three healthy volun-
teers were collected, anticoagulated with an EDTA salt
and stored in glass containers. This lot of blood samples
was used to simulate the practical use of the devices as
the first group; in the second group, a water/ethanol
mixture with a density (ρ) of 0.9378 g/ml (20°C) was uti-
lized to extract the DEHP under the same conditions
(the same extraction media volume, the same dripping
rate and the same ambient temperature) as those for the
first group. The results of this determination are pro-
vided in Table 1 and Figure 6.
While a small sample size was used and only one type
of medical device was tested, the outcomes based on the
scenario above are quite different when comparing the
blood samples with the water/ethanol mixture. Appar-
ently, the extraction ability of the water/ethanol mixture
is much higher than that of blood. In addition, the effect
of using blood with different properties has not been
taken into consideration. For example, blood with high
cholesterol and high triglyceride contents might be able
to extract more DEHP than blood from healthy people.
A study on the correlation between an increase in serum
DEHP concentration and the endogenous serum lipid
concentration has indicated a weak association between
















0.1 94.23 2.33 92.43 3.88
1 94.23 4.51 91.04 6.71
10 101.53 8.80 98.90 0.57
100 89.58 7.16 98.15 2.24
180, 200a 94.60 5.02 95.35 7.86
a180 μg/mL and 200 μg/mL were spiked for the ethanol/water test and blood
test, respectively.relative increase in the serum DEHP concentration. In
contrast, no correlation was found between an increase
in the DEHP concentration and the concentration of
cholesterol in serum (Buchta et al. 2003). As a result,
when blood is not available, the use of an alternative
medium is preferred, and if the result of the DEHP de-
termination is acceptable, then no further tests need to
be performed using blood.Methodology validation
Repeatability and accuracy
The linear range of the determination of DEHP using
this study is 0.1-200 μg/mL when using n-hexane as the
solvent. The correlation coefficient is greater than 0.999.
To validate the repeatability, standard solutions with
four different concentrations have been used to repre-
sent high, intermediate, low, and very low concentra-
tions within the linear range of 0.1-200 μg/mL, and 6
replicates were used at each concentration. The results
are listed in Table 2.
In addition, a recovery test was used to evaluate the
accuracy of the method and was conducted by spiking
samples at 5 different concentrations levels using 3 repli-
cates at each level. The results are listed in Table 3 and
Figure 7.
Intermediate precision
The experiment was performed using the same method,
instrument, and device lots (transfusion sets were used),
but on different days by different analysts. Each group pre-
pared 6 sample replicates (the water/ethanol mixture was
used as the extraction medium). The results are listed in
Table 4.
Detection limit (DL) and Quantitation limit (QL)
As has been discussed in section DEHP background of
this paper, normally there is always DEHP background
present during the testing procedure because of various
contamination sources, and as a result, lowering the
background DEHP would be a primary goal before sam-
ple testing, especially for low concentration level tests.
Furthermore, the DEHP background level plays an im-
portant role when determining the DL and QL values.
When using n-hexane, which has been screened and
found to contain almost no background DEHP (Figure 5),
to prepare a series of very low level DEHP standards,
after injecting them into the instrument and using the
method based on using signal to noise ratios of approxi-
mately 3:1 and 10:1 to assess the DL and QL, the DL
and QL of the method in the SIM mode were approxi-
mately 1 ng/mL and 2.5 ng /mL, respectively. However,
in most cases, background DEHP would present, al-
















Figure 7 Results of the recovery validation.
Table 5 Sample determination results
Medical devices Extraction media DEHP released, mg
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blood itself. In this case, the DL and QL value determi-
nations usually refer to ICH Q2 (R1) 6.3 and 7.3 and use





where σ = the standard deviation of the response and
S = the slope of the calibration curve.
The σ values were obtained in this study by injecting
blank samples (ethanol/water mixture and whole blood)
and calculating the standard deviation of these responses
using 10 replicates of each. The calculated DL and QL
values in this study were 3.08 ng/mL and 9.35 ng/mL for
blood and 2.91 ng/mL and 8.81 ng/mL for the ethanol/
water mixture, respectively. It should be noted that just
as described in section DEHP background, the screening
test results within the same regent groups indicated that
there might be different DEHP background levels present;
therefore, sometimes it may be necessary to report the
DEHP DL and QL case by case when the regent supplier
or even the lot number is changed.
Specificity
It has been verified that the analytical procedure is specific
for the determination of DEHP and that the solvents, ex-
traction media, including the water/ethanol solution, blood
components, and blood anticoagulants, including both the
EDTA salt and heparins, do not interfere with the DEHP.
Sample determination results
The DEHP from the three different types of medical de-
vices listed was determined using the established GC-
MS method described. The devices were single use
transfusion sets, single use leukocyte-reducing filters andTable 4 Intermediate precision test results
Group Mean (n = 6) μg/mL Total RSD (%) within the
two groups (n = 12)
Group 1 13.17
9.00
Group 2 12.66tube systems for haemodialysis. The exposure route to
human beings for all of these devices is the parenteral
route. The sample preparation methods were conducted
simulating the clinical use of these devices. The test re-
sults are listed in Table 5.
According to the FDA DEHP safety assessment docu-
ment, the tolerable intake (TI) values for DEHP are
0.6 mg/kg(body mass)/day for the parenteral route, and
in the absence of specific information, body masses of
70 kg for adults, 10 kg for children, and 3.5 kg for neo-
nates should be used (ISO 10993-17 2002). Using the TI
value of 0.6 mg/kg(body mass)/day, the calculated DEHP
tolerable exposures (TEs) for human beings are 42 mg/day
for adults, 6 mg for children and 2.1 mg for neonates, re-
spectively. Apparently, all of the determination results are
less than the TE value for adults, which means that the
DEHP released from these medical devices is safe for
adults. For the transfusion set, the result from the alterna-
tive media is more than the TE value for neonates, but
when blood was used, which will be the practical contact
media during clinical use, the released DEHP was much
less than the TE value for neonates. This result indicates
that the amount of DEHP released from this product is
also safe, even for neonates. When reviewing the tube sys-
tem for haemodialisis use, the result is much higher than
the TE values for children and neonates; therefore, a fur-
ther extraction with blood may be needed if the product is
intended for these types of populations. If those results
can still not conform to the TE values of these two groups,











a100 mL of the extraction media (both the water/ethanol mixture and blood)
was used.
bBlood from three healthy volunteers
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should be noted that with more and more concern with
the toxicity of DEHP during the past ten years, especially
the increased risk in children (U.S.FDA 2001), many prod-
ucts have been developed using an alternative plasticizer
or an alternative material for children and neonates.
Conclusion
A useful and convenient alternative solvent for human
blood is recommended for use in a screening test to
evaluate the DEHP released from medical devices that
have contact with blood. A GC-MS method has been
established for the determination of the amount of
DEHP in both the alternate extraction solution and
whole blood. This method is feasible for analyzing the
DEHP released, and it is more practical to use the alter-
native extraction solution instead of human blood.
While extraction with an alternative solvent is a useful
and sensitive screen, it is not likely to be representative
of actual bio-availability of DEHP when used clinically in
contact with whole blood. If an extraction using ethanol/
water detects no or safe levels of DEHP, then this result
is strong evidence that there is no need to proceed fur-
ther. However if extraction with ethanol/water produces
levels of DEHP which approach or exceed the TI, this
does not necessarily translate to hazardous exposure to
DEHP in clinical use. Instead, in such circumstances an
appropriate next step would be to investigate actual
availability in further studies with whole blood.
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